Global Targeted Protein Degradation Platform 麻豆原创 Growth (Status and Outlook) 2024-2030

Publication ID:

LPI04240032

Publication Date:

April 16, 2024

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

IT Services [2]

Software [3]

Computing & Electronics [4]

Description:

The global Targeted Protein Degradation Platform market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
LPI (publisher)' newest research report, the 鈥淭argeted Protein Degradation Platform Industry Forecast鈥� looks at past sales and reviews total world Targeted Protein Degradation Platform sales in 2023, providing a comprehensive analysis by region and market sector of projected Targeted Protein Degradation Platform sales for 2024 through 2030. With Targeted Protein Degradation Platform sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Protein Degradation Platform industry.
This Insight Report provides a comprehensive analysis of the global Targeted Protein Degradation Platform landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Targeted Protein Degradation Platform portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Targeted Protein Degradation Platform market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Protein Degradation Platform and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Protein Degradation Platform.
United States market for Targeted Protein Degradation Platform is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Targeted Protein Degradation Platform is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Targeted Protein Degradation Platform is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Targeted Protein Degradation Platform players cover Arvinas, Kymera Therapeutics, Plexium, Nurix and Amphista, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Protein Degradation Platform market by product type, application, key players and key regions and countries.
Segmentation by type
PROTAC Platform
Dual-platform (Molecular Glue and PROTAC)
Segmentation by application
Cancer
Autoimmune Diseases
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Arvinas
Kymera Therapeutics
Plexium
Nurix
Amphista
Cullgen
Hengrui Pharmaceuticals
Hinova Pharmaceuticals
Ranok Therapeutics

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Targeted Protein Degradation Platform 麻豆原创 Size 2019-2030
2.1.2 Targeted Protein Degradation Platform 麻豆原创 Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Targeted Protein Degradation Platform Segment by Type
2.2.1 PROTAC Platform
2.2.2 Dual-platform (Molecular Glue and PROTAC)
2.3 Targeted Protein Degradation Platform 麻豆原创 Size by Type
2.3.1 Targeted Protein Degradation Platform 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Targeted Protein Degradation Platform 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Targeted Protein Degradation Platform Segment by Application
2.4.1 Cancer
2.4.2 Autoimmune Diseases
2.4.3 Other
2.5 Targeted Protein Degradation Platform 麻豆原创 Size by Application
2.5.1 Targeted Protein Degradation Platform 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Targeted Protein Degradation Platform 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 Targeted Protein Degradation Platform 麻豆原创 Size by Player
3.1 Targeted Protein Degradation Platform 麻豆原创 Size 麻豆原创 Share by Players
3.1.1 Global Targeted Protein Degradation Platform Revenue by Players (2019-2024)
3.1.2 Global Targeted Protein Degradation Platform Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Targeted Protein Degradation Platform Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Targeted Protein Degradation Platform by Regions
4.1 Targeted Protein Degradation Platform 麻豆原创 Size by Regions (2019-2024)
4.2 Americas Targeted Protein Degradation Platform 麻豆原创 Size Growth (2019-2024)
4.3 APAC Targeted Protein Degradation Platform 麻豆原创 Size Growth (2019-2024)
4.4 Europe Targeted Protein Degradation Platform 麻豆原创 Size Growth (2019-2024)
4.5 Middle East & Africa Targeted Protein Degradation Platform 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Targeted Protein Degradation Platform 麻豆原创 Size by Country (2019-2024)
5.2 Americas Targeted Protein Degradation Platform 麻豆原创 Size by Type (2019-2024)
5.3 Americas Targeted Protein Degradation Platform 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Targeted Protein Degradation Platform 麻豆原创 Size by Region (2019-2024)
6.2 APAC Targeted Protein Degradation Platform 麻豆原创 Size by Type (2019-2024)
6.3 APAC Targeted Protein Degradation Platform 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Targeted Protein Degradation Platform by Country (2019-2024)
7.2 Europe Targeted Protein Degradation Platform 麻豆原创 Size by Type (2019-2024)
7.3 Europe Targeted Protein Degradation Platform 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Targeted Protein Degradation Platform by Region (2019-2024)
8.2 Middle East & Africa Targeted Protein Degradation Platform 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Targeted Protein Degradation Platform 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Targeted Protein Degradation Platform 麻豆原创 Forecast
10.1 Global Targeted Protein Degradation Platform Forecast by Regions (2025-2030)
10.1.1 Global Targeted Protein Degradation Platform Forecast by Regions (2025-2030)
10.1.2 Americas Targeted Protein Degradation Platform Forecast
10.1.3 APAC Targeted Protein Degradation Platform Forecast
10.1.4 Europe Targeted Protein Degradation Platform Forecast
10.1.5 Middle East & Africa Targeted Protein Degradation Platform Forecast
10.2 Americas Targeted Protein Degradation Platform Forecast by Country (2025-2030)
10.2.1 United States Targeted Protein Degradation Platform 麻豆原创 Forecast
10.2.2 Canada Targeted Protein Degradation Platform 麻豆原创 Forecast
10.2.3 Mexico Targeted Protein Degradation Platform 麻豆原创 Forecast
10.2.4 Brazil Targeted Protein Degradation Platform 麻豆原创 Forecast
10.3 APAC Targeted Protein Degradation Platform Forecast by Region (2025-2030)
10.3.1 China Targeted Protein Degradation Platform 麻豆原创 Forecast
10.3.2 Japan Targeted Protein Degradation Platform 麻豆原创 Forecast
10.3.3 Korea Targeted Protein Degradation Platform 麻豆原创 Forecast
10.3.4 Southeast Asia Targeted Protein Degradation Platform 麻豆原创 Forecast
10.3.5 India Targeted Protein Degradation Platform 麻豆原创 Forecast
10.3.6 Australia Targeted Protein Degradation Platform 麻豆原创 Forecast
10.4 Europe Targeted Protein Degradation Platform Forecast by Country (2025-2030)
10.4.1 Germany Targeted Protein Degradation Platform 麻豆原创 Forecast
10.4.2 France Targeted Protein Degradation Platform 麻豆原创 Forecast
10.4.3 UK Targeted Protein Degradation Platform 麻豆原创 Forecast
10.4.4 Italy Targeted Protein Degradation Platform 麻豆原创 Forecast
10.4.5 Russia Targeted Protein Degradation Platform 麻豆原创 Forecast
10.5 Middle East & Africa Targeted Protein Degradation Platform Forecast by Region (2025-2030)
10.5.1 Egypt Targeted Protein Degradation Platform 麻豆原创 Forecast
10.5.2 South Africa Targeted Protein Degradation Platform 麻豆原创 Forecast
10.5.3 Israel Targeted Protein Degradation Platform 麻豆原创 Forecast
10.5.4 Turkey Targeted Protein Degradation Platform 麻豆原创 Forecast
10.5.5 GCC Countries Targeted Protein Degradation Platform 麻豆原创 Forecast
10.6 Global Targeted Protein Degradation Platform Forecast by Type (2025-2030)
10.7 Global Targeted Protein Degradation Platform Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Arvinas
11.1.1 Arvinas Company Information
11.1.2 Arvinas Targeted Protein Degradation Platform Product Offered
11.1.3 Arvinas Targeted Protein Degradation Platform Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Arvinas Main Business Overview
11.1.5 Arvinas Latest Developments
11.2 Kymera Therapeutics
11.2.1 Kymera Therapeutics Company Information
11.2.2 Kymera Therapeutics Targeted Protein Degradation Platform Product Offered
11.2.3 Kymera Therapeutics Targeted Protein Degradation Platform Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 Kymera Therapeutics Main Business Overview
11.2.5 Kymera Therapeutics Latest Developments
11.3 Plexium
11.3.1 Plexium Company Information
11.3.2 Plexium Targeted Protein Degradation Platform Product Offered
11.3.3 Plexium Targeted Protein Degradation Platform Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Plexium Main Business Overview
11.3.5 Plexium Latest Developments
11.4 Nurix
11.4.1 Nurix Company Information
11.4.2 Nurix Targeted Protein Degradation Platform Product Offered
11.4.3 Nurix Targeted Protein Degradation Platform Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 Nurix Main Business Overview
11.4.5 Nurix Latest Developments
11.5 Amphista
11.5.1 Amphista Company Information
11.5.2 Amphista Targeted Protein Degradation Platform Product Offered
11.5.3 Amphista Targeted Protein Degradation Platform Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Amphista Main Business Overview
11.5.5 Amphista Latest Developments
11.6 Cullgen
11.6.1 Cullgen Company Information
11.6.2 Cullgen Targeted Protein Degradation Platform Product Offered
11.6.3 Cullgen Targeted Protein Degradation Platform Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 Cullgen Main Business Overview
11.6.5 Cullgen Latest Developments
11.7 Hengrui Pharmaceuticals
11.7.1 Hengrui Pharmaceuticals Company Information
11.7.2 Hengrui Pharmaceuticals Targeted Protein Degradation Platform Product Offered
11.7.3 Hengrui Pharmaceuticals Targeted Protein Degradation Platform Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 Hengrui Pharmaceuticals Main Business Overview
11.7.5 Hengrui Pharmaceuticals Latest Developments
11.8 Hinova Pharmaceuticals
11.8.1 Hinova Pharmaceuticals Company Information
11.8.2 Hinova Pharmaceuticals Targeted Protein Degradation Platform Product Offered
11.8.3 Hinova Pharmaceuticals Targeted Protein Degradation Platform Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 Hinova Pharmaceuticals Main Business Overview
11.8.5 Hinova Pharmaceuticals Latest Developments
11.9 Ranok Therapeutics
11.9.1 Ranok Therapeutics Company Information
11.9.2 Ranok Therapeutics Targeted Protein Degradation Platform Product Offered
11.9.3 Ranok Therapeutics Targeted Protein Degradation Platform Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 Ranok Therapeutics Main Business Overview
11.9.5 Ranok Therapeutics Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.